Calidi Biotherapeutics Q4 net loss $4.1M; FY net loss $25.6M; CLD-401 IND on track for end-2026

Calidi Biotherapeutics, Inc.

Q4 net loss $4.1M ($0.57/sh); FY net loss $25.6M ($5.95/sh) vs $23.8M ($35.70/sh) in 2024.
Cash and restricted cash $5.8M at Dec 31, 2025, down from $9.8M a year ago; raised $6.5M in offering/ATM.
Partnered with Avance Clinical to initiate CLD-401 first-in-human trial in Australia; plans to file IND by end-2026.
Presented in situ T-cell engager data at AACR-IO; partnered with Matica Bio for GMP manufacturing of CLD-401.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 1.0

Calidi Biotherapeutics, Inc. reported the fourth quarter and full year ended December 31, 2025 results: net income $25.6 million, or $5.95 per share, for the year ended December 31, 2025, EPS $5.95 per share.

Period: the fourth quarter and full year ended December 31, 2025
Net income: $25.6 million, or $5.95 per share, for the year ended December 31, 2025
EPS: $5.95 per share
Result: reported results

Exact text from the filing

The company reported a net loss attributable to common stockholders of $4.1 million, or $0.57 per share, for the three months ended December 31, 2025

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 1.0

Period: the fourth quarter and full year ended December 31, 2025
Net income: $25.6 million, or $5.95 per share, for the year ended December 31, 2025
EPS: $5.95 per share
Result: reported results

Exact text from the filing

The company reported a net loss attributable to common stockholders of $25.6 million, or $5.95 per share, for the year ended December 31, 2025

View on SEC.gov

1436 earnings releases filed in the last 30 days. Browse all earnings releases →

Calidi Biotherapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-26-013236

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.